Yissum - Research Development Company of the Hebrew University

Predictive Cancer Classification Algorithm Based on Similar Gene-Expression Signatures

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

This novel computerized method will assist physicians in diagnosis, in prediction of clinical outcomes and possibly in formulating therapeutic approaches for treating a wide variety of cancers. The method is a general one and can successfully work for any disease type if an adequate size sample of microarrays is provided
PATENT WAS ABANDONED, commercialization possible based on implied know-how only.
Project ID : 19-2006-164

Description of the technology

Genomic big data analysis enabling better diagnostics and therapeutic approach


Oncology software, cancer diagnostics, personalized medicine

Development Stage

TRL 5Validated in relevant operation environment

Patent Status

U.S. patent 8,423,296,2013


  • Current cancer diagnostic` methods rely on descriptive histopathological data.
  • New technology measures patient genomic data against detailed classification of cancer types from databases of measured tumour genomic expression profiles
  • The method monitors genetic changes enabling improved accuracy of diagnosis
  • Since molecular changes often precede morphological changes, genetic assessment of cancer patients may be used for early detection of the disease.

Our Innovation

This new tool measures the similarity between gene data derived from DNA gene tests (microarray, deep sequencing, nanostring ..) of a patients malignant tissue with sets of gene test data from pre-classified malignancies. The actual similarity distance obtained provides a powerful and sensitive diagnostic tool for each patient.

Key Features

  • Increased diagnostic and detection accuracy, reclassification into new subgroups. A clear similarity value to different clinical states.
  • Enables cancer diagnosis, prediction of clinical outcomes and formulation of therapeutic approach
  • General method may be used for any type of disease if an adequate size sample of microarrays from previously classified disease is available

Development Milestones

Seeking industry cooperation for further development with companies that can prepare datasets

The Opportunity

25 million people in Japan, Europe and North America have cancer; 10.1 million additional cases diagnosed worldwide each year. By 2020, that number will grow to 15 million new cases annually. (World Health Organization)

Researcher Informationbioinfo.md.huji.ac.il/contact.asp

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Yoav Smith
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • diagnostics

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.